V3 CTL epitope density in a single recombinant molecule antigen differentially affects the number and activity of primary and memory CD8+ T cells

Vaccine

Volumn 26, Issue 6, 2008, Pages 845-852

  Lu, Lu ^a   Zhu, Yun ^a   Diao, Junchen ^a   Wang, Zuguang ^a   Chen, Ying Hua ^a  

^a Laboratory of Immunology   (China)

Author keywords

Epitope density; T cell response; V3 CTL epitope

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; PROTEIN V3L1; PROTEIN V3L2; PROTEIN V3L4; PROTEIN V3L8; RECOMBINANT DNA; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CD8+ T LYMPHOCYTE; CELL ACTIVITY; CELL COUNT; CELL DENSITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFECT; DRUG MECHANISM; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNE RESPONSE; MEMORY T LYMPHOCYTE; PRIORITY JOURNAL;

AIDS VACCINES; ANIMALS; CYTOTOXICITY TESTS, IMMUNOLOGIC; EPITOPES, T-LYMPHOCYTE; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; IMMUNOLOGIC MEMORY; LYMPHOCYTE COUNT; MICE; MICE, INBRED BALB C; PEPTIDE FRAGMENTS; T-LYMPHOCYTES, CYTOTOXIC; VACCINES, DNA;

EID: 38349008378     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.11.022     Document Type: Article

References (32)

1. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4 3 (2004) 199-210
2. Cohen J. Is an effective HIV vaccine feasible?. Science 309 5731 (2005) 99
3. Fowke K.R., Nagelkerke N.J., Kimani J., Simonsen J.N., Anzala A.O., Bwayo J.J., et al. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya. Lancet 348 9038 (1996) 1347-1351
4. McMichael A.J., and Phillips R.E. Escape of human immunodeficiency virus from immune control. Annu Rev Immunol 15 (1997) 271-296
5. Koff W.C., Johnson P.R., Watkins D.I., Burton D.R., Lifson J.D., Hasenkrug K.J., et al. HIV vaccine design: insights from live attenuated SIV vaccines. Nat Immunol 7 1 (2006) 19-23
6. Zinkernagel R.M. On natural and artificial vaccinations. Annu Rev Immunol 21 (2003) 515-546
7. Kaech S.M., Wherry E.J., and Ahmed R. Effector and memory T-cell differentiation: Implications for vaccine development. Nat Rev Immunol 2 4 (2002) 251-262
8. Levine M.M., and Sztein M.B. Vaccine development strategies for improving immunization: the role of modern immunology. Nat Immunol 5 5 (2004) 460-464
9. Targett G. Vaccine efficacy, and immunity affecting transmission. Parassitologia 41 1-3 (1999) 433-436
10. Jegerlehner A., Storni T., Lipowsky G., Schmid M., Pumpens P., and Bachmann M.F. Regulation of IgG antibody responses by epitope density and CD21-mediated costimulation. Eur J Immunol 32 11 (2002) 3305-3314
11. Liu W.L., Zou P., Liu Z.Q., Yun L., Jian D., and Chen Y.H. High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity. Vaccine 23 3 (2004) 366-371
12. Liu W.L., and Chen Y.H. High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: a novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol 35 2 (2005) 505-514
13. Wherry E.J., McElhaugh M.J., and Eisenlohr L.C. Generation of CD8(+) T cell memory in response to low, high, and excessive levels of epitope. J Immunol 168 9 (2002) 4455-4461
14. Bullock T.N.J., Mullins D.W., and Engelhard V.H. Antigen density presented by dendritic cells in vivo differentially affects the number and avidity of primary, memory, and recall CD8(+) T cells. J Immunol 170 4 (2003) 1822-1829
15. Berzofsky J.A. Development of artificial vaccines against HIV using defined epitopes. Faseb J 5 10 (1991) 2412-2418
16. Luo L., Li Y., Chang J.S., Cho S.Y., Kim T.Y., Choi M.J., et al. Induction of V3-specific cytotoxic T lymphocyte responses by HIV gag particles carrying multiple immunodominant V3 epitopes of gp120. Virology 240 2 (1998) 316-325
17. Casement K.S., Nehete P.N., Arlinghaus R.B., and Sastry K.J. Cross-reactive cytotoxic T lymphocytes induced by V3 loop synthetic peptides from different strains of human immunodeficiency virus type 1. Virology 211 1 (1995) 261-267
18. Nehete P.N., Casement K.S., Arlinghaus R.B., and Sastry K.J. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120. Cell Immunol 160 2 (1995) 217-223
19. Liu Z., and Chen Y.H. Design and construction of a recombinant epitope-peptide gene as a universal epitope-vaccine strategy. J Immunol Methods 285 1 (2004) 93-97
20. Wherry E.J., Puorro K.A., Porgador A., and Eisenlohr L.C. The induction of virus-specific CTL as a function of increasing epitope expression: responses rise steadily until excessively high levels of epitope are attained. J Immunol 163 7 (1999) 3735-3745
21. Wolkers M.C., Brouwenstijn N., Bakker A.H., Toebes M., and Schumacher T.N. Antigen bias in T cell cross-priming. Science 304 5675 (2004) 1314-1317
22. Beignon A.S., Skoberne M., and Bhardwaj N. Type I interferons promote cross-priming: more functions for old cytokines. Nat Immunol 4 10 (2003) 939-941
23. Rea D., Johnson M.E., Havenga M.J., Melief C.J., and Offringa R. Strategies for improved antigen delivery into dendritic cells. Trends Mol Med 7 3 (2001) 91-94
24. Liu Y., Zhao T.J., Yan Y.B., and Zhou H.M. Increase of soluble expression in Escherichia coli cytoplasm by a protein disulfide isomerase gene fusion system. Protein Expr Purif 44 2 (2005) 155-161
25. Alexander-Miller M.A., Derby M.A., Sarin A., Henkart P.A., and Berzofsky J.A. Supraoptimal peptide-major histocompatibility complex causes a decrease in bc1-2 levels and allows tumor necrosis factor alpha receptor II-mediated apoptosis of cytotoxic T lymphocytes. J Exp Med 188 8 (1998) 1391-1399
26. Takeshita T., Takahashi H., Kozlowski S., Ahlers J.D., Pendleton C.D., Moore R.L., et al. Molecular analysis of the same Hiv peptide functionally binding to both a class-I and a class-Ii Mhc molecule. J Immunol 154 4 (1995) 1973-1986
27. Nakagawa Y., Takeshita T., Berzofsky J.A., and Takahashi H. Analysis of the mechanism for extracellular processing in the presentation of human immunodeficiency virus-1 envelope protein-derived peptide to epitope-specific cytotoxic T lymphocytes. Immunology 101 1 (2000) 76-82
28. Klinman D.M. Use of CpG oligodeoxynucleotides as immunoprotective agents. Expert Opin Biol Ther 4 6 (2004) 937-946
29. Klinman D.M. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat Rev Immunol 4 4 (2004) 249-258
30. Kojima Y., Xin K.Q., Ooki T., Hamajima K., Oikawa T., Shinoda K., et al. Adjuvant effect of multi-CpG motifs on an HIV-1 DNA vaccine. Vaccine 20 23-24 (2002) 2857-2865
31. Carvalho L.H., Hafalla J.C., and Zavala F. ELISPOT assay to measure antigen-specific murine CD8(+) T cell responses. J Immunol Methods 252 1-2 (2001) 207-218
32. Clerici M., Lucey D.R., Zajac R.A., Boswell R.N., Gebel H.M., Takahashi H., et al. Detection of cytotoxic T lymphocytes specific for synthetic peptides of gp160 in HIV-seropositive individuals. J Immunol 146 7 (1991) 2214-2219